Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Nitric Oxide Signaling Pathway

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Human responses to the DNA prime/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC Class I-restricted epitopes.

PloS one·2025

Same author

Prospective Assessment of Symptoms to Evaluate Asymptomatic SARS-CoV-2 Infections in a Cohort of Health Care Workers.

Open forum infectious diseases·2022

Same author

Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers.

Emerging infectious diseases·2022

Same author

Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers.

Open forum infectious diseases·2022

Same author

A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.

PloS one·2021

Same author

Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers.

medRxiv : the preprint server for health sciences·2021

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Published on: February 16, 2022

Investigating the potential of statin medications as a nitric oxide (NO) release agent to decrease decompression

Christopher A Duplessis¹, David Fothergill

¹Navy Hospital Portsmouth, 620 John Paul Jones Circle, Portsmouth, VA 23708, United States. mduplessis4@cox.net

Medical Hypotheses

|September 15, 2007

Summary

This summary is machine-generated.

Nitric oxide (NO) and statins may prevent decompression sickness (DCS) and arterial gas emboli (AGE) injury by reducing bubble formation and inflammation. These agents offer novel pharmacologic strategies for hyperbaric and surgical exposures.

More Related Videos

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

Analytical Techniques for Assaying Nitric Oxide Bioactivity

Analytical Techniques for Assaying Nitric Oxide Bioactivity

Published on: June 18, 2012

Related Experiment Videos

Last Updated: Jul 11, 2026

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Published on: February 16, 2022

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

Analytical Techniques for Assaying Nitric Oxide Bioactivity

Analytical Techniques for Assaying Nitric Oxide Bioactivity

Published on: June 18, 2012

Area of Science:

Biochemistry
Pharmacology
Physiology

Background:

Decompression sickness (DCS) and arterial gas emboli (AGE) injuries arise from bubble pathophysiology during hyperbaric or hypobaric exposures, surgery, and trauma.
Current treatments primarily rely on recompression, highlighting the need for novel pharmacologic interventions.
Understanding the biochemical mechanisms of bubble formation is crucial for developing preventative and therapeutic strategies.

Purpose of the Study:

To review the biochemical effects of nitric oxide (NO) release agents on bubble pathophysiology.
To explore the potential of NO-mediated pathways and statins in reducing DCS risk and AGE injury.
To discuss the mechanisms by which NO and statins may mitigate bubble-related damage.

Main Methods:

Literature review focusing on nitric oxide (NO) and statin mechanisms.
Analysis of biochemical and biophysical processes influencing bubble formation and pathophysiology.
Examination of pleiotropic effects of statins, including endothelial nitric oxide synthase (eNOS) up-regulation.

Main Results:

Exogenous NO or endogenous NO up-regulation may decrease gaseous nuclei, reduce bubble adherence, and inhibit inflammatory/coagulation cascades.
Statins preserve endothelial integrity, reduce ischemia/reperfusion injury, and modulate inflammation and coagulation.
Statin-induced lipid reduction may alter plasma rheology and surface tension, potentially reducing bubble generation.

Conclusions:

Nitric oxide (NO) release agents and statins show promise as pharmacologic interventions to reduce DCS risk and AGE injury.
Statins, with their proven safety and pleiotropic effects, are attractive candidates for mitigating bubble-related pathologies.
Further research into NO-mediated mechanisms and statin efficacy could lead to novel non-recompressive treatments for DCS and AGE.